Future of Cancer Immunotherapy Biomarkers

Where is the field of immune biomarkers going beyond PD-L1 in the next few years?

November 27, 2015

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015

Immunosurveillance, Immunoscore & Personalized Cancer Immunotherapy – an interview with Jérôme Galon

Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.

October 30, 2015

Is there a biomarker for cetuximab in colon cancer?

Finding a biomarker for EGFR monoclonal antibodies in colon cancer has proven elusive but things may be a-changin'...

October 22, 2015

Why combine radiation with cancer immunotherapy?

Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.

October 21, 2015

New oncology targets emerge from ECC 2015 – Part 1

Some promising new clinical targets emerged at ECC in Vienna, including DLL3 in SCLC, TRK gene rearrangements, Notch3 and PTK7. What did we think of the data and what issues should you look out for?

October 19, 2015

Controversies in lung cancer immunotherapy

Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test? The debate is heating up!

October 26, 2015

Where are the breakthroughs coming in Soft Tissue Sarcoma?

Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma

October 6, 2015

Potential of Checkpoint Inhibitors in Ovarian Cancer

Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types

October 5, 2015

What’s hot at Day 3 of European Cancer Congress?

Commentary on Day 3 of the European Cancer Congress in Vienna

September 28, 2015

ECC Day 2 Highlights – Checkpoints in Lung and Bladder Cancer

Commentary on Day 2 of the European Cancer Congress in Vienna

September 27, 2015

ECC Day 1 Highlights – the battle for Advanced Renal Cell Carcinoma

Highlights from Day 1 of the ECC 2015 (ECCO) meeting in Vienna

September 25, 2015

ECC Vienna Preview 2 Oral Presentations

What's hot at ECCO 2015 in the oral sessions? An in-depth preview of what we can expect to hear about in Vienna...

September 10, 2015

ECC Vienna Preview 1 Late Breaking Abstracts

What's hot in the 2015 ECCO late breaking abstracts in Vienna? Find out here...

September 8, 2015

Atezolizumab PDL1 Checkpoint Inhibitor will change Bladder Cancer Treatment

Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer

September 3, 2015

BMS and Exelixis announce new renal cell cancer data

Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?

July 22, 2015

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016

Dr Oliver Sartor shares his thoughts on Prostate Cancer data at ECCO 2013

Dr Oliver Sartor, one of the leading experts in Prostate Cancer shares his thoughts on the prostate cancer data presented at ECCO 2013.

September 30, 2013

ECCO Day 3: Update on alectinib, PD-L1, PI3K and MEK

Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours

September 30, 2013

ECCO Highlights Day 2: Breast and Ovarian Cancer

The latest data on BioMarin's PARP inhibitor BMN 673 in breast and ovarian cancer from ECCO 2013

September 29, 2013

ECCO 2013: AZD9291 shows early promise in T790M NSCLC

Promising preliminary phase 1 data for AstraZeneca’s AZD9291 in T790M+ NSCLC presented today at the European Cancer Congress (ECCO 2013) is good news for lung cancer patients.

September 29, 2013

ECCO 2013: Is ODM-201 too late to the prostate cancer party?

At ECCO 2013 in Amsterdam, positive data was presented from the phase 1/2 clinical trial for ODM-201 (Orion) a second generation AR antagonist. In contrast the data for ASP9521 (Astellas), a novel androgen biosynthesis inhibitor was negative.

September 29, 2013

ECCO 2013 Notes from the Road – Day 1

Update on ipilimumab, AP26113, T-DM1, everolimus and others from Day 1 at the 2013 ECCO meeting in Amsterdam.

September 28, 2013

Preview of key ALK lung cancer abstracts at ECCO 2013

Review of the key abstracts in EML4-ALK lung cancer abstracts being presented at ECCO 2013 in Amsterdam.

September 23, 2013
ECCO 2013 Conference Amsterdam

A top line look at the PD-1 and PD-L1 abstracts at ECCO 2013

A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.

September 19, 2013

How new approaches in targeted immunotherapy with anti-PD-1 and PD-L1 may change cancer research

Overview of anti-PD-1 and PD-L1 immunotherapies plus ASCO 2013 data in melanoma and lung cancer.

September 18, 2013

Preview of 2013 European Cancer Congress in Amsterdam

2013 European Cancer Congress organized by ECCO takes place in Amsterdam from September 27 to October 1st. This is a preview of some of the abstracts to watch out for at the meeting.

September 16, 2013